Journal of Antimicrobial Chemotherapy (2002) 49, 37-41
© 2002 The British Society for Antimicrobial Chemotherapy
Supplement |
Amphotericin B nephrotoxicity
Nephrology Department, Pitié-Salpêtrière Hospital, Boulevard de l’Hôpital, Paris 750013, France
Abstract
The use of amphotericin B limited by dose-dependent nephrotoxicity. Elevated creatinine associated with amphotericin B is not only a marker for renal dysfunction, but is also linked to an increase in hospital costs and a substantial risk for the use of haemodialysis and a higher mortality rate. Therefore, amphotericin B nephrotoxicity is not a benign complication and its prevention is essential. Several manipulations have been proposed to minimize amphotericin B-induced nephrotoxicity. Mannitol and frusemide administration are reported to be protective based on anecdotal observational reports. Small prospective and randomized trials do not suggest a protective effect. Three new formulations have been developed in attempts to improve both efficacy and tolerability: amphotericin B in a lipid complex (ABLC; Abelcet); amphotericin B colloidal dispersion; and liposomal amphotericin B (AmBisome). Three prospective randomized studies have clearly shown that AmBisome is less nephrotoxic than amphotericin B. In a double-blind randomized trial significantly fewer patients receiving AmBisome had nephrotoxic effects. This significant reduction in azotaemia was also observed among subgroups of patients receiving concomitant therapy with nephrotoxic agents. Moreover, there were fewer patients with hypokalaemia in the group receiving AmBisome. A recent multicentre double-blind study has shown that AmBisome (3 or 5 mg/kg/day) has a better safety profile than Abelcet (5 mg/kg). Patients in both AmBisome treatment groups experienced less chills/rigors, less nephrotoxicity based on a doubling of serum creatinine, and fewer toxic reactions resulting in discontinuation of therapy. In conclusion, amphotericin B nephrotoxicity is observed frequently. It clearly increases patient mortality. Nephrotoxicity must be recognized early, based on tubular abnormalities and a mild increase in serum creatinine. Its prevention relies on the detection and suppression of risk factors and the use of AmBisome.
Notes
* Tel: 33-1-42-17-72-29; Fax: 33-1-42-17-72-32; E-mail: gilbert.deray{at}psl.ap-hop-paris.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Ellis, R. Bernsen, H. Ali-Zadeh, J. Kristensen, U. Hedstrom, L. Poughias, M. Bresnik, A. Al-Essa, and D. A. Stevens A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever J. Med. Microbiol., November 1, 2009; 58(11): 1474 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michallet and J. I. Ito Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation J. Clin. Oncol., July 10, 2009; 27(20): 3398 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yano, Y. Itoh, E. Kawamura, A. Maeda, N. Egashira, M. Nishida, H. Kurose, and R. Oishi Amphotericin B-Induced Renal Tubular Cell Injury Is Mediated by Na+ Influx through Ion-Permeable Pores and Subsequent Activation of Mitogen-Activated Protein Kinases and Elevation of Intracellular Ca2+ Concentration Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1420 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Amaral, A. L. Bocca, A. M. Ribeiro, J. Nunes, D. L. G. Peixoto, A. R. Simioni, F. L. Primo, Z. G. M. Lacava, R. Bentes, R. Titze-de-Almeida, et al. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis J. Antimicrob. Chemother., March 1, 2009; 63(3): 526 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Paterson, K. David, M. Mrsic, P. Cetkovsky, X.-H. Weng, J. Sterba, G. Krivan, D. Boskovic, M. Lu, L.-P. Zhu, et al. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC(R): data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry J. Antimicrob. Chemother., December 1, 2008; 62(6): 1392 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Y. Hachem, A. A. Langston, J. R. Graybill, J. R. Perfect, L. D. Pedicone, H. Patino, and I. I. Raad Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment J. Antimicrob. Chemother., December 1, 2008; 62(6): 1386 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lionakis, G. Samonis, and D. P. Kontoyiannis Endocrine and Metabolic Manifestations of Invasive Fungal Infections and Systemic Antifungal Treatment Mayo Clin. Proc., September 1, 2008; 83(9): 1046 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Isnard, P. Tilleul, J.-P. Laporte, P. Chevallier, A. Pigneux, A. Lafuma, L. Mahi, and G. Deray A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment Nephrol. Dial. Transplant., October 1, 2007; 22(10): 3090 - 3091. [Full Text] [PDF]
|
|
|
|
|
|
S. Mohan, S. Ahmed, B. Alimohammadi, M. Jaitly, J.-T. Cheng, and V. A. Pogue Proteinuria lowers the risk of amphotericin B-associated hypokalaemia J. Antimicrob. Chemother., September 1, 2007; 60(3): 690 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. ECHEVARRIA, C. SEAS, M. CRUZ, E. CHAVEZ, M. CAMPOS, J. CIEZA, E. GOTUZZO, and A. LLANOS ORAL REHYDRATION SOLUTION TO PREVENT NEPHROTOXICITY OF AMPHOTERICIN B Am J Trop Med Hyg, December 1, 2006; 75(6): 1108 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Vogelsinger, S. Weiler, A. Djanani, J. Kountchev, R. Bellmann-Weiler, C. J. Wiedermann, and R. Bellmann Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion J. Antimicrob. Chemother., June 1, 2006; 57(6): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lincopan, E. M. Mamizuka, and A. M. Carmona-Ribeiro Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments J. Antimicrob. Chemother., May 1, 2005; 55(5): 727 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Falk, M. Hacham, A. Nyska, J. F. Foley, A. J. Domb, and I. Polacheck Induction of interleukin-1{beta}, tumour necrosis factor-{alpha} and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan J. Antimicrob. Chemother., May 1, 2005; 55(5): 713 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simitsopoulou, E. Roilides, J. Dotis, M. Dalakiouridou, F. Dudkova, E. Andreadou, and T. J. Walsh Differential Expression of Cytokines and Chemokines in Human Monocytes Induced by Lipid Formulations of Amphotericin B Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1397 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mimee, C. Labbe, R. Pelletier, and R. R. Belanger Antifungal Activity of Flocculosin, a Novel Glycolipid Isolated from Pseudozyma flocculosa Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1597 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Courtney, A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin, and S. Swan Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease J. Clin. Pharmacol., February 1, 2005; 45(2): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A Hemstreet Antimicrobial-Associated Renal Tubular Acidosis Ann. Pharmacother., June 1, 2004; 38(6): 1031 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Larabi, N. Pages, F. Pons, M. Appel, A. Gulik, J. Schlatter, S. Bouvet, and G. Barratt Study of the toxicity of a new lipid complex formulation of amphotericin B J. Antimicrob. Chemother., January 1, 2004; 53(1): 81 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gerbaud, F. Tamion, C. Girault, K. Clabault, S. Lepretre, J. Leroy, and G. Bonmarchand Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome) J. Antimicrob. Chemother., February 1, 2003; 51(2): 473 - 475. [Full Text] [PDF]
|
|